The role of peritoneal alternatively activated macrophages in the process of peritoneal fibrosis related to peritoneal dialysis

International Journal of Molecular Sciences

Volumn 14, Issue 5, 2013, Pages 10369-10382

  Wang, Jie ^a   Jiang, Zong Pei ^a   Su, Ning ^a   Fan, Jin Jin ^a   Ruan, Yi Ping ^a   Peng, Wen Xing ^a   Li, Ya Fang ^a   Yu, Xue Qing ^a  

^a SUN YAT SEN UNIVERSITY   (China)

Author keywords

Alternatively activated macrophages; Liposome encapsulated clodronate; Peritoneal dialysis; Peritoneal fibrosis related to PD

Indexed keywords

ARGINASE 1; CHEMOKINE RECEPTOR CCR7; CHITINASE 3 LIKE 3 PROTEIN; CLODRONIC ACID; COLLAGEN TYPE 1; FIBRONECTIN; LIPOSOME; MANNOSE RECEPTOR; MEMBRANE PROTEIN; TRANSFORMING GROWTH FACTOR ALPHA; UNCLASSIFIED DRUG; ARG1 PROTEIN, MOUSE; ARGINASE; BETA N ACETYLHEXOSAMINIDASE; CELL SURFACE RECEPTOR; CHI3L3 PROTEIN, MOUSE; LECTIN; MANNOSE BINDING LECTIN; TRANSFORMING GROWTH FACTOR BETA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL COUNT; CELL METABOLISM; CONTROLLED STUDY; DISEASE ASSOCIATION; DOWN REGULATION; DRUG EFFECT; ENCAPSULATION; FEMALE; IMMUNOFLUORESCENCE TEST; MACROPHAGE ACTIVATION; MOLECULAR DYNAMICS; MOUSE; NONHUMAN; PERITONEAL DIALYSIS; PERITONEAL FIBROSIS; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; UPREGULATION; WESTERN BLOTTING; ANIMAL; C57BL MOUSE; CLASSIFICATION; CONFOCAL MICROSCOPY; GENETICS; METABOLISM; PERITONEUM MACROPHAGE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ANIMALS; ARGINASE; BETA-N-ACETYLHEXOSAMINIDASES; BLOTTING, WESTERN; COLLAGEN TYPE I; FEMALE; FIBRONECTINS; LECTINS; LECTINS, C-TYPE; MACROPHAGE ACTIVATION; MACROPHAGES, PERITONEAL; MANNOSE-BINDING LECTINS; MICE, INBRED C57BL; MICROSCOPY, CONFOCAL; PERITONEAL DIALYSIS; PERITONEAL FIBROSIS; RECEPTORS, CELL SURFACE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TRANSFORMING GROWTH FACTOR BETA;

EID: 84878222678     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms140510369     Document Type: Article

References (34)

1. Grassmann, A.; Gioberge, S.; Moeller, S.; Brown, G. ESRD patients in 2004: Global overview of patient numbers, treatment modalities and associated trends. Nephrol. Dial. Transplant 2005, 20, 2587-2593.
2. Aroeira, L.S.; Aguilera, A.; Sanchez-Tomero, J.A.; Bajo, M.A.; Del, P.G.; Jimenez-Heffernan, J.A.; Selgas, R.; Lopez-Cabrera, M. Epithelial to mesenchymal transition and peritoneal membrane failure in peritoneal dialysis patients: pathologic significance and potential therapeutic interventions. J. Am. Soc. Nephrol. 2007, 18, 2004-2013.
3. Krediet, R.T.; Lindholm, B.; Rippe, B. Pathophysiology of peritoneal membrane failure. Perit Dial. Int. 2000, 20, S22-S42.
4. Yung, S.; Chan, T.M. Pathophysiological changes to the peritoneal membrane during PD-related peritonitis: The role of mesothelial cells. Mediat. Inflamm. 2012, 2012, 484167.
5. Di Paolo, N.; Sacchi, G. Atlas of peritoneal histology. Perit Dial. Int. 2000, 20, S5-S96.
6. Williams, J.D.; Craig, K.J.; Topley, N.; von Ruhland, C.; Fallon, M.; Newman, G.R.; Mackenzie, R.K.; Williams, G.T. Morphologic changes in the peritoneal membrane of patients with renal disease. J. Am. Soc. Nephrol. 2002, 13, 470-479.
7. Mosser, D.M.; Edwards, J.P. Exploring the full spectrum of macrophage activation. Nat. Rev. Immunol. 2008, 8, 958-969.
8. Gordon, S. Alternative activation of macrophages. Nat. Rev. Immunol. 2003, 3, 23-35.
9. Jaguin, M.; Houlbert, N.; Fardel, O.; Lecureur, V. Polarization profiles of human M-CSF-generated macrophages and comparison of M1-markers in classically activated macrophages from GM-CSF and M-CSF origin. Cell Immunol. 2013, 281, 51-61.
10. Martinez, F.O.; Gordon, S.; Locati, M.; Mantovani, A. Transcriptional profiling of the human monocyte-to-macrophage differentiation and polarization: New molecules and patterns of gene expression. J. Immunol. 2006, 177, 7303-7311.
11. Badylak, S.F.; Valentin, J.E.; Ravindra, A.K.; Mccabe, G.P.; Stewart-Akers, A.M. Macrophage phenotype as a determinant of biologic scaffold remodeling. Tissue Eng. A 2008, 14, 1835-1842.
12. Martinez, F.O.; Helming, L.; Gordon, S. Alternative activation of macrophages: An immunologic functional perspective. Annu. Rev. Immunol. 2009, 27, 451-483.
13. Stein, M.; Keshav, S.; Harris, N.; Gordon, S. Interleukin 4 potently enhances murine macrophage mannose receptor activity: A marker of alternative immunologic macrophage activation. J. Exp. Med. 1992, 176, 287-292.
14. Murphy, B.S.; Bush, H.M.; Sundareshan, V.; Davis, C.; Hagadone, J.; Cory, T.J.; Hoy, H.; Hayes, D.J.; Anstead, M.I.; Feola, D.J. Characterization of macrophage activation states in patients with cystic fibrosis. J. Cyst. Fibros. 2010, 9, 314-322.
15. Higashi-Kuwata, N.; Jinnin, M.; Makino, T.; Fukushima, S.; Inoue, Y.; Muchemwa, F.C.; Yonemura, Y.; Komohara, Y.; Takeya, M.; Mitsuya, H.; et al. Characterization of monocyte/macrophage subsets in the skin and peripheral blood derived from patients with systemic sclerosis. Arthritis Res. Ther. 2010, 12, R128.
16. Murray, L.A.; Rosada, R.; Moreira, A.P.; Joshi, A.; Kramer, M.S.; Hesson, D.P.; Argentieri, R.L.; Mathai, S.; Gulati, M.; Herzog, E.L., et al. Serum amyloid P therapeutically attenuates murine bleomycin-induced pulmonary fibrosis via its effects on macrophages. PLoS One 2010, 5, e9683.
17. Mathai, S.K.; Gulati, M.; Peng, X.; Russell, T.R.; Shaw, A.C.; Rubinowitz, A.N.; Murray, L.A.; Siner, J.M.; Antin-Ozerkis, D.E.; Montgomery, R.R., et al. Circulating monocytes from systemic sclerosis patients with interstitial lung disease show an enhanced profibrotic phenotype. Lab Invest. 2010, 90, 812-823.
18. Chu, D.; Du, M.; Hu, X.; Wu, Q.; Shen, J. Paeoniflorin attenuates schistosomiasis japonica-associated liver fibrosis through inhibiting alternative activation of macrophages. Parasitology 2011, 138, 1259-1271.
19. Gibbons, M.A.; Mackinnon, A.C.; Ramachandran, P.; Dhaliwal, K.; Duffin, R.; Phythian-Adams, A.T.; van Rooijen, N.; Haslett, C.; Howie, S.E.; Simpson, A.J. Ly6Chi monocytes direct alternatively activated profibrotic macrophage regulation of lung fibrosis. Am. J. Respir. Crit. Care Med. 2011, 184, 569-581.
20. Ahmad, S.; North, B.V.; Qureshi, A.; Malik, A.; Bhangal, G.; Tarzi, R.M.; Brown, E.A.; Tam, F.W. CCL18 in peritoneal dialysis patients and encapsulating peritoneal sclerosis. Eur. J. Clin. Invest. 2010, 40, 1067-1073.
21. Bellon, T.; Martinez, V.; Lucendo, B.; Del, P.G.; Castro, M.J.; Aroeira, L.S.; Rodriguez-Sanz, A.; Ossorio, M.; Sanchez-Villanueva, R.; Selgas, R., et al. Alternative activation of macrophages in human peritoneum: Implications for peritoneal fibrosis. Nephrol. Dial. Transplant. 2011, 26, 2995-3005.
22. Lopez-Navarrete, G.; Ramos-Martinez, E.; Suarez-Alvarez, K.; Aguirre-Garcia, J.; Ledezma-Soto, Y.; Leon-Cabrera, S.; Gudino-Zayas, M.; Guzman, C.; Gutierrez-Reyes, G.; Hernandez-Ruiz, J., et al. Th2-associated alternative Kupffer cell activation promotes liver fibrosis without inducing local inflammation. Int. J. Biol. Sci. 2011, 7, 1273-1286.
23. Van Rooijen, N. The liposome-mediated macrophage "suicide" technique. J. Immunol. Methods 1989, 124, 1-6.
24. Van Rooijen, N.; Van Nieuwmegen, R. Elimination of phagocytic cells in the spleen after intravenous injection of liposome-encapsulated dichloromethylene diphosphonate. An enzyme-histochemical study. Cell Tissue Res. 1984, 238, 355-358.
25. Murray, L.A.; Chen, Q.; Kramer, M.S.; Hesson, D.P.; Argentieri, R.L.; Peng, X.; Gulati, M.; Homer, R.J.; Russell, T.; van Rooijen, N.; et al. TGF-beta driven lung fibrosis is macrophage dependent and blocked by Serum amyloid P. Int. J. Biochem. Cell Biol. 2011, 43, 154-162.
26. Biewenga, J.; van der Ende, M.B.; Krist, L.F.; Borst, A.; Ghufron, M.; van Rooijen, N. Macrophage depletion in the rat after intraperitoneal administration of liposome-encapsulated clodronate: depletion kinetics and accelerated repopulation of peritoneal and omental macrophages by administration of Freund's adjuvant. Cell Tissue Res. 1995, 280, 189-196.
27. Ha, H.; Cha, M.K.; Choi, H.N.; Lee, H.B. Effects of peritoneal dialysis solutions on the secretion of growth factors and extracellular matrix proteins by human peritoneal mesothelial cells. Perit. Dial. Int. 2002, 22, 171-177.
28. Kushiyama, T.; Oda, T.; Yamada, M.; Higashi, K.; Yamamoto, K.; Oshima, N.; Sakurai, Y.; Miura, S.; Kumagai, H. Effects of liposome-encapsulated clodronate on chlorhexidine gluconate-induced peritoneal fibrosis in rats. Nephrol. Dial. Transplant. 2011, 26, 3143-3154.
29. Huang, C.; Ogawa, R. Fibroproliferative disorders and their mechanobiology. Connect Tissue Res. 2012, 53, 187-196.
30. Takagawa, S.; Lakos, G.; Mori, Y.; Yamamoto, T.; Nishioka, K.; Varga, J. Sustained activation of fibroblast transforming growth factor-beta/Smad signaling in a murine model of scleroderma. J. Invest. Dermatol. 2003, 121, 41-50.
31. Lv, Z.D.; Wang, H.B.; Li, F.N.; Wu, L.; Liu, C.; Nie, G.; Kong, B.; Qu, H.L.; Li, J.G. TGF-beta1 induces peritoneal fibrosis by activating the Smad2 pathway in mesothelial cells and promotes peritoneal carcinomatosis. Int. J. Mol. Med. 2012, 29, 373-379.
32. Hu, W.; Jiang, Z.; Zhang, Y.; Liu, Q.; Fan, J.; Luo, N.; Dong, X.; Yu, X. Characterization of infiltrating macrophages in high glucose-induced peritoneal fibrosis in rats. Mol. Med. Report 2012, 6, 93-99.
33. Van Rooijen, N.; Sanders, A. Liposome mediated depletion of macrophages: mechanism of action, preparation of liposomes and applications. J. Immunol. Methods 1994, 174, 83-93.
34. Pfaffl, M.W. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res. 2001, 29, e45.